Compositions and Methods for Inhibiting Gene Expressions by Fang, Po-Yu et al.
1111111111111111111inuuuuu
(12) United States Patent
Williams et al.
(54) COMPOSITIONS AND METHODS FOR
INHIBITING GENE EXPRESSIONS
(71) Applicant: GEORGIA TECH RESEARCH
CORPORATION, Atlanta, GA (US)
(72) Inventors: Loren D. Williams, Atlanta, GA (US);
Po-Yu Fang, Atlanta, GA (US);
Chiaolong Hsiao, Atlanta, GA (US);
Justin Williams, Atlanta, GA (US)
(73) Assignee: Georgia Tech Research Corporation,
Atlanta, GA (US)
(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.
(21) Appl. No.: 14/911,645
(22) PCT Filed: Sep. 11, 2014
(86) PCT No.: PCT/US2014/055149
§ 371 (c)(1),
(2) Date: Feb. 11, 2016
(87) PCT Pub. No.: W02015/038746
PCT Pub. Date: Mar. 19, 2015
(65) Prior Publication Data
US 2016/0194613 Al Jul. 7, 2016
Related U.S. Application Data
(60) Provisional application No. 61/876,450, filed on Sep.
11, 2013.
(51) Int. Cl.
C12N 15/11 (2006.01)
C12N 7/00 (2006.01)
C12N 15/88 (2006.01)
AOIN 57/16 (2006.01)
C12N 15/113 (2010.01)
C12N 15186 (2006.01)
(52) U.S. Cl.
CPC ............... C12N 7/00 (2013.01); AOIN 57/16
(2013.01); C12N 15/1137 (2013.01); C12N
15/88 (2013.01); C12N 15186 (2013.01); C12N
2310114 (2013.01); C12N 2795/18123
(2013.01); C12N 2795118142 (2013.01); C12N
2795118151 (2013.01); C12N 2 795/1 81 52
(2013.01)
(58) Field of Classification Search
CPC .............................. C12N 7/00; C12N 15/1137
See application file for complete search history.
(56) References Cited
U.S. PATENT DOCUMENTS
2013/0167267 Al* 6/2013 Arhancet ............. C07K 14/005
800/298
2016/0177299 Al * 6/2016 Arhancet ............... A61K 48/00
435/91.32
(io) Patent No.: US 9,932,563 B2
(45) Date of Patent: Apr. 3, 2018
FOREIGN PATENT DOCUMENTS
WO 2007068747 6/2007
WO 2010047839 4/2010
WO 2011116226 9/2011
OTHER PUBLICATIONS
Cadena-Nava et al. Journal of Viriology p. 3318-3326, 2011.*
Naskalska et al. Polish Journal of Micorbiology 2015, 64, 3-13.*
Scow et al. Molecular Therapy 17, 767-777, 2009.*
Bhaumik et al. Oncogene 2008, 27, 5643-5647.*
Fiedler et al. Angew Chem Int Ed Engl Dec. 2010 49:9648-9651.*
Agrawal, et al., RNA interference: biology, mechanism, and appli-
cations, Microbiol Mot Biol Rev., pp. 67(4):657 85 (2003).
Beekwilder, et al., Secondary structure model for the last two
domains of single-stranded RNA phage Q beta, J Mot Biol.,
247(5):903-17 (1995).
Bowman, et al., Preparation of long templates for RNA in vitro
transcription by recursive PCR, Methods Mot Biol., 941:19-41
(2012).
Galaway and Stockley, MS2 viruslike particles: a robust,
semisynthetic targeted drug delivery platform, Mot Pharm.,
10(1):59-68 (2013).
Ituvenne and Smagghe, Mechanisms of dsrna uptake in insects and
potential of rnai for pest control: A review , J Insect Physiol.,
56:227-35 (2010).
Lau, et al., Evolution and protein packaging of small molecule RNA
aptamers , ACS Nano, 5:7722-9 (2011).
Milhavet, et al., RNA interference in biology and medicine,
Pharmacol Rev., 55: 629-648 (2003).
Oey, et al., Rnai knock-down of lhcbml, 2 and 3 increases photo-
synthetic h2 production efficiency of the green alga
Chlamydomonas reinhardtii, PLoS One, 8:e61375 (2013).
Pan, et al., Development of a microrna delivery system based on
bacteriophage ms2 virus-like particles , FEBS J, 279:1198-1208
(2012).
Rhee, et al., Colorful virus-like particles: Fluorescent protein pack-
aging by the q beta capsid, Biomacromolecules, 12:3977-81 (2011).
Schneider, et al., Selection of high affinity RNA ligands to the
bacteriophage R17 coat protein, J Mot Biol, 228(3):862-9 (1992).
Sledz and Williams, RNA interference in biology and disease,
Blood, 106 (3):787-94 (2005).
Smith, et al., Reengineering viruses and virus-like particles through
chemical functional ization strategies , Curr Opin Biotechnol,
24(4):620-6 (2013).
(Continued)
Primary Examiner Brian A Whiteman
(74) Attorney, Agent, or Firm Smith, Gambrell &
Russell, LLP
(57) ABSTRACT
A combined packing and assembly method that efficiently
packs ribonucleic acid (RNA) into virus like particles
(VLPs) has been developed. The VLPs can spontaneously
assemble and load RNA in vivo, efficiently packaging spe-
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ference activity, or is a precursor of a RNA capable of
causing interference activity. Compositions and methods for
the efficient expression, production and purification of VLP-
RNAs are provided. VLP-RNAs can be used for the storage
of RNA for long periods, and provide the ability to deliver
RNA in stable form that is readily taken up by cells.
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COMPOSITIONS AND METHODS FOR
INHIBITING GENE EXPRESSIONS
CROSS REFERENCE TO RELATED
APPLICATONS: 5
This application is a 371 application of International
Application No. PCT/2014/055149, filed Sep. 11, 2014,
which claims priority to and benefit of U.S. Provisional
Patent Application No. 61/876,450 filed on Sep. 11, 2013. i0
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
This invention was made with Government Support under 15
Agreement NAI awarded to Loren D. Williams by the
NASA Astrobiology Institute, Contract number
NNA09DA78A. The Government has certain rights in the
invention.
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REFERENCE TO SEQUENCE LISTING
The sequence listing submitted on Feb. 11, 2016, as a txt
file named "GTRC_6427_ST25.txt," created on Sep. 11,
2014, and having a size of 3,575 bytes is hereby incorpo- 25
rated by reference pursuant to 37 C.F.R.§ 1.52(e)(5).
FIELD OF THE INVENTION
The invention relates to the field of RNA interference and 30
in particular to use of virus like particles in iRNA.
BACKGROUND OF THE INVENTION
In RNA interference (RNAi), an iRNA (an RNA molecule 35
with gene interference activity) of appropriate sequence will
down-regulate a given gene by preventing a specific mes-
senger RNA (mRNA) from producing protein. RNAi has
been rapidly developed into a potent and broadly applied
tool in medicine, biofuels, agriculture and basic research 40
(Sledz and Williams, Blood, 106(3):787-794 (2005)).
Production, packaging, storage and delivery of RNA
remains the central challenge to the therapeutic application
of RNAi technology. Purified RNAs are notoriously
unstable and are extremely vulnerable to degradation, for 45
example by nucleases, hydroxyl radicals, UV light, and
Mg2'-mediated inline attack. The low-stability of RNAs
precludes storage for long periods of time and severely
limits the potential range of distribution and application
methods for RNA-based pharmaceutical compounds. As a 50
result, RNA-based applications commonly require costly
and inefficient chemical modification of RNA for stabiliza-
tion and delivery.
Therefore, it is an object of the invention to provide
methods and compositions for the improved delivery of 55
RNA to a target cell or a host.
It is still another object of the invention to provide
methods and compositions for down-regulating gene expres-
sion in a host.
60
SUMMARY OF THE INVENTION
A combined packing and assembly method that efficiently
packs ribonucleic acid (RNA) into virus like particles
(VLPs) has been developed. In an exemplary method VLPs 65
spontaneously assemble and efficiently load specifically
designed RNA in vivo. The VLPs confer stability to RNA
2
against degradation by nucleases, hydroxyl radicals, UV
light, and Mg2'-mediated inline attack. VLPs that contain
biologically active RNA have been designed, produced and
tested. The RNA is loaded in the particles at a density of
about three RNA molecules per viral particle. The purity of
the RNA in the VLPs can be controlled by RNA sequence
and length. The RNA can be designed to inhibit a target gene
when introduced to a target cell or organism. For example,
double-stranded RNA corresponding to the target gene can
be packaged into the VLPs. The RNA-loaded VLPs are
taken up by target cells, including human cells, and the
interfering RNA (iRNA) machinery of the target cell cuts the
double-stranded RNA into short interfering RNA (siRNA)
molecules, for example into RNA fragments of about 21 to
23 consecutive nucleotides in length. The siRNA down
regulates expression of the target gene (see Milhavet, et al.,
Pharmacol Rev, 55: 629-648 (2003); Agrawal et al., Micro-
bio. Mol. Biol. Rev., pp. 657-685 (2003)).
The disclosed compositions and methods enable the pro-
duction of VLPs that contain RNA. VLPs containing RNA
are called "VLP-RNAs". VLPs protect the enclosed RNAs
from chemical, photo- and enzymatic degradation. The RNA
within a VLP is stabilized against degradation by nucleases,
hydroxyl radicals, UV light, and Mg2'-mediated inline
attack. VLPs eliminate requirements for chemical modifi-
cation to stabilize and deliver RNA and provide the ability
to deliver RNA in a stable form that is readily taken up by
cells. VLPs containing RNA capable of interference activity
can deliver RNA targeting the expression of any gene in any
organism that contains active iRNA machinery, including
most eukaryotes.
In one embodiment virus like particles encapsulating
ribonucleic acid (collectively referred to as VLP-RNAs)
include a viral particle formed from the coat proteins of a
bacteriophage and one or more RNA polynucleotides. The
coat proteins encapsulate the one or more RNAs within the
viral particle. The RNAs contain a nucleotide sequence with
high amity for the bacteriophage or virus coat protein to
enable packaging of the RNA into the VLP. The efficiency
of packaging is further controlled by the length and folding
propensities of the RNA. In some embodiments RNAs
contain one or more nucleotide sequences complementary to
a target gene. The size of the RNA contained within the VLP
can be fewer than 50 nucleotides to many kilo-bases in
length.
RNAs encapsulated within VLPs can be single-stranded
or double-stranded RNA (dsRNA). In some embodiments
the RNAs optionally contain a nucleotide sequence that
facilitates purification of the RNA by amity chromatogra-
phy. In one embodiment the nucleotide sequence that facili-
tates purification forms an RNA aptamer. Typically the
sequence of the RNA within the VLP is derived from
eukaryotic mRNA or ncRNA. The RNA can be single- or
double-stranded. In other embodiments, the RNA is not a
naturally occurring RNA. In some embodiments the RNA
contains thermal-stable tetraloops, G-quartets and other
motifs that confer desired folding propensities.
In one embodiment the RNA within the VLP is a precur-
sor RNA capable of producing iRNA that inhibits expression
of a target gene. Exemplary iRNAs include micro RNA
(miRNA) and short interfering RNA (siRNA) (see, for
example, Zeng, et al., PNAS, 100:9779-9784 (2003)). Typi-
cally the target gene is a eukaryotic gene. In some embodi-
ments the virus coat protein is the q beta coat protein. In one
embodiment the RNA is packaged within the VLPs at an
RNA/VLP molar ratio of about 3.6.
US 9,932,563 B2
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Abacterial cell producing VLPs that contain RNA is also
provided. In one embodiment the bacterial cell is an Escheri-
chia coli cell. In some embodiments the RNA and the VLP
genes are encoded by the same expression construct. In one
embodiment the expression of the VLP genes and RNA are
under the control of the same promoter. In another embodi-
ment the expression of the VLP genes and the RNA are
under the control of different promoters. The one or more
promoters can optionally be inducible promoters.
Methods for the in vivo expression and packaging of
RNA within VLPs are also included. Typically the methods
include engineering a recombinant host cell, for example a
bacterial cell, to express one or more genes encoding one or
more RNAs of a target gene or a complement RNA thereof.
The one or more RNAs are engineered to contain a high
amity tag for a bacteriophage or virus coat protein. The
recombinant host cell is engineered to also express one or
more genes encoding the coat protein of a bacteriophage
corresponding to the recognition tag within the RNA. The
methods also include expressing the RNA and coat protein
constructs in the cells as well as purifying the resulting VLPs
containing RNA.
A kit for the in vivo production of VLPs containing RNA
is also described. Typically, the kit includes containers
housing one or more expression vectors for the expression of
RNA and virus like particles within Escherichia coli. One of
the expression vectors contains one or more genes encoding
the coat protein of a bacteriophage or virus. One of the
expression vectors contains an expression cassette for the
expression of the RNA. In some embodiments the expres-
sion cassette contains a multiple cloning site for the incor-
poration of a nucleotide sequence complementary to that of
the desired target. The multiple cloning site is located
directly downstream of a sequence with high amity for the
bacteriophage or virus coat protein. The expression cassette
enables production of a RNA containing both the desired
target sequence and the sequence with high amity for the
coat protein. In one embodiment each container vessel
contains a defined quantity of a single expression vector.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an image of a denaturing polyacrylamide gel of
RNA which was packaged into a VLP by co-expression of
the capsid protein and the RNA in vivo. The most intense
band in the lane labeled "product RNA" corresponds to the
packaged RNA including the duo tags, which is 751 nucleo-
tides in length. mRNA encoding the capsid protein is shown
as the faint band in the left lane below the position of the 650
nt size marker band. The single band corresponding to 650
nucleotides is the shown in the lane on the right.
FIGS. 2A-2F show how RNA is protected by VLPs in
unfavorable environments. FIGS. 2A, 2C, and 2E are dena-
turing polyacrylamide gels of naked RNA and VLP-pack-
aged RNA for different time intervals. FIGS. 213, 2D, and 2F
are bar graphs showing the major RNA band level expressed
as a percentage of the initial value was plotted versus time
with different treatment for each of the denaturing polyacry-
lamide gels. Naked RNA and VLP-packaged RNA are
treated (FIGS. 2A-2B) Hydroxyl radical cleavage: samples
were treated with free hydroxyl radicals that were created
from the Fenton reaction., (FIGS. 2C-2D) Metal ion-based
cleavage: samples were treated with 150 mM Mg2l ions at
37° C., (FIGS. 2E-2F) Spontaneous degradation: samples
were treated without Mg2l ions at 37° C.
FIG. 3 is a scatter dot plot to illustrate the survival of the
Eastern subterranean termite Reticulitermes flavipes (as a
4
fraction of the starting quantity), over time (in days), for
termites consuming filter paper containing 600 µg VLP-
sRNA (■) or a control containing buffer (0), respectively.
FIGS. 4A-4C are photomicrographs showing the uptake
5 of dual-color virus like particles (VLPs) by HeLa cells: The
Q(3-VLPs encapsulate the green fluorescent protein (GFP) in
vitro, where the particle surface is chemically conjugated
with the fluorescent dye, Dylight 633. The HeLa cells were
incubated with 125 nM of [Q(3-VLP-GFP-Dylight633] at
10 37° C. for 0 (FIG. 4A), 1 (FIG. 413), and 2 days (FIG. 4C).
If Q(3-VLP encapsulates green fluorescent proteins and
forms a complex, the co-localization will possess unique
emission. Therefore, one can track GFP-loaded Q(3-VLPs
15 using confocal laser scanning microscopy.
FIGS. 5A-5D are fluorescent photomicrographs showing
suppression of gene expression using VLP-pre-miRNA: The
in vivo VLP-packaged pre-miRNA knocks down the GFP
gene expression in HeLa cells. The pre-miRNA designed to
20 knock down the GFP gene expression is packed by the
production of VLP simultaneously in vivo. Prior to the
incubation of the in vivo VLP-packaged pre-miRNA with
HeLa cells, the GFP gene was first chemically transfected
into HeLa cells. The GFP gene expression level was then
25 observed by using fluorescence microscopic techniques. The
HeLa cells are treated with (FIG. 5A) as control, no GFP
gene transfection, (FIG. 513) the GFP gene transfection,
(FIG. 5C) the in vivo VLP-packaged miRNA after the GFP
gene transfection, and (FIG. 5D) the wild type VLP contains
30 no designed pre-miRNA after the GFP gene transfection.
The images were taken for each condition setup after 24
hours. The VLP concentration is 1 uM. In the images, white
spots show the GFP gene expressions.
35 FIG. 6 is a bar graph of % GFP Expression in HeLa cells
treated as indicated. Quantitation of GFP suppression in
HeLa cells: The gene expression level of GFP in HeLa cells
with the treatments of in vivo VLP-packaged pre-miRNA
(VLP-pre-miRNA) in a concentration fashion for 24 (grey
40 bar) and 48 (black bar) hours. The GFP gene expression
levels, reported here as percentage, were analyzed by the BD
LSR II Flow Cytometer. The wild type VLP (WT-VLP),
which contains no designed pre-miRNA to knock down the
GFP gene expression, is used to test the cell toxicity. The
45 standard deviations (black vertical line) for each condition
are shown on each bar.
FIG. 7 is a graph showing GFP suppression (% GFP
Expression) curve with VLP-packaged-pre-miRNA at 8
different concentrations (nM) up to 48 hours: Shown are
50 one-phase decay curve models fitted to the GFP gene
expression data in HeLa cells with the treatments of in vivo
VLP-packaged pre-miRNA (VLP-pre-miRNA) in a concen-
tration fashion for 24 (dot line) and 48 (inverted triangle
line) hours. The concentrations for VLP-pre-miRNA to
55 inhibit 50% of the GFP expression (ICso) in HeLa cells are
335 nM in 24 hours, and 100 nM in 48 hours.
DETAILED DESCRIPTION OF THE
INVENTION
60
I. Definitions
The term "host cell' refers to prokaryotic and eukaryotic
cells into which a recombinant expression vector can be
introduced.
65 The terms "transformed" and "transfected" encompass
the introduction of a nucleic acid (e.g., a vector) into a cell
by a number of techniques known in the art.
US 9,932,563 B2
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The term "specifically binds" to a target refers to a
binding reaction which is determinative of the presence of
the molecule in the presence of a heterogeneous population
of other biologics.
"Localization Signal" or "Localization Sequence" or
"Recognition Sequence" or "Targeting Signal" or "Recog-
nition Sequence" or "Recognition Tag" or "Recognition
polynucleotide" are used interchangeably and refer to a
signal that directs a molecule to a specific cell, tissue,
organelle, or intracellular region. The signal can be poly-
nucleotide, polypeptide, or carbohydrate moiety or can be an
organic or inorganic compound sufficient to direct an
attached molecule to a desired location.
The term "vector" refers to a replicon, such as a plasmid,
phage, or cosmid, into which another DNA segment may be
inserted so as to bring about the replication of the inserted
segment. The vectors described herein can be expression
vectors.
The term "expression vector" refers to a vector that
includes one or more expression control sequences.
The term "gene" refers to a DNA sequence that encodes
through its template or messenger RNA a sequence of amino
acids characteristic of a specific peptide, polypeptide, or
protein. The term "gene" also refers to a DNA sequence that
encodes an RNA product. The term gene as used herein with
reference to genomic DNA includes intervening, non-coding
regions as well as regulatory regions and can include 5' and
3' ends.
The term "iRNA" refers to a ribonucleic acid (RNA)
molecule which can bind by complementary base pairing to
a target messenger RNA transcripts (mRNAs), usually caus-
ing translational repression or target degradation which
results in gene silencing reduced gene expression. Exem-
plary iRNA molecules include but are not limited to short
interfering RNA (siRNA) and micro RNA (miRNA).
The terms "target gene" and "target sequence" are used
interchangeably and refer to a sequence that can hybridize
with an iRNA and induce gene silencing.
The terms "individual," "individual," "subject," and
"patient" are used interchangeably herein, and refer to a
mammal, including, but not limited to, humans, rodents,
such as mice and rats, and other laboratory animals.
The terms "virus like particle", or "VLP" refer to a viral
capsid formed from the assembly of viral coat proteins, that
does not contain any viral genetic material. A "VLP-RNA"
is a recombinant virus like particle containing a capsid of
viral or bacteriophage coat proteins and one or more RNA
molecules enclosed within the capsid.
II. Compositions for Delivery of RNA
Virus-like particles (VLPs) represent a promising delivery
vehicle for RNAs. VLPs are symmetric, multi-protein struc-
tures that self-assemble into 100 mu-scale particles with
virus-like morphology. Compositions for the delivery of
RNA which employ VLPs as vessels containing RNA cargo
are disclosed for a range of applications, including thera-
peutics, agriculture, the development of biofuels and as tools
for basic research.
A. RNAs Capable of Interference Activity
RNA is a biological polymer with key roles in transcrip-
tion, translation and many other biological functions. Over
the last several decades RNA has been found to play a
variety of regulatory roles in gene expression. An RNA
polynucleotide with interference activity of a given gene
will down-regulate the gene by causing degradation of the
6
specific messenger RNA (mRNA) with the corresponding
complementary sequence and preventing the production of
protein (see Sledz and Williams, Blood, 106(3):787-794
(2005)). When an RNA molecule forms complementary
5 Watson-Crick base pairs with an mRNA, it induces mRNA
cleavage by accessory proteins. The source of the RNA can
be viral infection, transcription, or introduction from exog-
enous sources.
VLPs that contain RNA designed for RNA interference
to 
activity are disclosed. VLPs containing RNA offer several
advantages over traditional RNA synthesis, packaging and
delivery methods. Specifically, in vivo synthesis of VLPs
containing RNA in Escherichia coli is cost-effective, adapt-
15 able and reliable.
B. Virus-Like Particles (VLPs)
Virus-like particles (VLPs) are symmetric, multi-protein
structures that self-assemble into 100 mu-scale particles
with virus-like morphology. On their exterior, VLPs
20 resemble bacteriophages and viruses, but internally, VLPs
can lack native genomic material (RNA or DNA required for
integration, reverse transcription, replication, infection,
etc.). Mutations and chemical modifications of VLP surfaces
confer a variety of chemical and physical properties to
25 VLPs. VLPs can be engineered as nano-containers that
protect and deliver ` cargo' such as RNA.
It is known that self-assembly of VLPs can follow natu-
rally from expression of viral envelope, capsid or coat
30 
proteins. A variety of small molecule and macromolecular
cargo can be incorporated into a VLP without influencing the
external morphology.
C. VLPs Containing RNA
VLPs are disclosed for the packaging, protection and
35 delivery of one or more RNA molecules within a viral capsid
vessel. Virus like particles containing RNA are called "VLP-
RNAs". RNA can be engineered to be packaged within
VLPs for the production of VLP-RNAs in a single-step
process (FIG. 1), according to the disclosed compositions
40 and methods.
1. Design of RNA for Incorporation into VLPs
RNAs are designed for use in a simple in vivo system (in
Escherichia coli) that spontaneously produces and packages
the RNA into VLPs.
45 To provide RNA for incorporation within VLPs, one or
more genes are built by recursive PCR or are cloned from a
cDNA or genomic library. Methods and techniques for the
production and design of cDNA are known in the art (see, for
example, Bowman, et al., Recombinant and in vitro RNA
50 
synthesis: Methods and protocols, methods in molecular
biology, Conn G L, editor. Springer Science, LLC. pp: 19-41
(2012)).
Typically the RNA includes a sequence complimentary to
55 
a target gene within a target organism, a viral coat protein
recognition tag and optionally an additional sequence or tag
for purification. The viral coat protein recognition tag facili-
tates the efficient and spontaneous uptake and assembly of
the RNA into VLPs. In some embodiments the RNA is
60 double stranded RNA. For the production of dsRNA, an
expression vector is designed to include the DNA template
from which both strands of RNA are to be derived.
a. RNA Stability
Production, packaging, storage and delivery of RNA
65 remains the central challenge to the therapeutic application
of RNAi technology. Purified RNAs are notoriously
unstable and are extremely vulnerable to degradation, for
US 9,932,563 B2
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example by nucleases, hydroxyl radicals, UV light, and
Mg2'-mediated inline attack. The low-stability of RNAs
precludes storage for long periods of time and severely
limits the potential range of distribution and application
methods for RNA-based pharmaceutical compounds. As a
result, RNA-based applications commonly require costly
and inefficient chemical modification of RNA for stabiliza-
tion and delivery. As we show in FIG. 2, RNA is protected
by VLPs from unfavorable conditions: Denaturing polyacry-
lamide gel analysis of naked RNA and VLP-packaged RNA
for different time intervals shows that the VLPs protect the
RNA. Hydroxyl radical cleavage, metal ion-based cleavage
(inline cleavage, and spontaneous degradation are all
severely attenuated by packaging in VLPs.
b. Gene Targeting
DNA templates can be designed to express RNAs that
have interfering activity against a specific target gene within
a specific target organism (FIG. 3.) In some embodiments
the target organism is a eukaryotic organism, such as a plant,
animal, alga or fungus. Typically the target gene is not a
naturally occurring viral gene.
In some embodiments the RNA can induce sequence-
specific silencing of the expression or translation of the
target polynucleotide, thereby down-regulating or prevent-
ing gene expression. In one embodiment the RNA can
induce the complete lack of expression of the target gene. In
another embodiment the RNA can reduce the level of
expression of the target gene below that of an untreated
control.
In some embodiments the RNA polynucleotide is a
double-stranded small interfering RNA (siRNA). Typically,
small interfering RNAs are between 21 and 23 nucleotides
in length. The siRNAs can be expressed within the host cell.
In other embodiments the RNA polynucleotide is a micro
RNA (miRNA). A miRNA is a small RNA that adopts a
hairpin conformation. The miRNA can be cleaved into
biologically active dsRNA within the target cell by the
activity of the endogenous cellular enzymes, for example the
enzyme Dicer and Dicer-like enzymes.
In some embodiments the RNA polynucleotide is a long
double stranded RNA molecule (dsRNA) that is at least 24
nucleotides in length. The dsRNA is processed into a bio-
logically active siRNA or 21-23 nucleotides by the activity
of the endogenous cellular enzymes, for example the
enzyme Dicer and Dicer-like enzymes within the target
organism. The dsRNA contains a nucleotide sequence that is
complimentary to one or more genes that are to be targeted
for down-regulation.
The one or more target genes can be of any desired
sequence. In some embodiments the sequence of the RNA is
100% complementary to the sequence of the target gene. In
other embodiments the RNA is less than 100% complemen-
tary to the target gene. In certain embodiments the RNA is
at least 95%, at least 90%, at least 85% or at least 80%
complementary to the nucleotide sequence of the target
gene, so that sequence variations that can occur, for example
due to genetic mutation, evolutionary divergence and strain
polymorphism can be tolerated.
The size of RNA contained within the VLP can be fewer
than 50 nucleotides to many kilo-bases in length.
The results of confocal laser scanning microscopy indi-
cate the spontaneous uptake of undecorated VLPs by mam-
malian cells (HeLa cells). This is the first demonstration of
uptake by human cells of undecorated Q(3 VLPs, although
uptake has been demonstrated for MS2 (Stockley, 2013).
8
Spontaneous Q(3 VLP uptake is fast (FIG. 4), plateauing
between 24 and 48 hours, which is roughly similar to what
was observed for MS2.
VLP-RNA interference of gene expression in vivo. Our
5 lab designed and constructed a new RNA expression vector
that generates hybrid pre-miRNA (hpmiRNA) directed
against Green Fluorescent Protein (GFP) expression (FIG.
5). These VLP-hpmiRNAs were produced and assembled in
vivo, (in E. coli) and isolated. VLP-hpmiRNAs were used to
10 treat HeLa cells that were expressing GFP. The hpmiRNA
was released in the HeLa cells and efficiently down-regu-
lated GFP expression. We have used fluorescence micros-
copy to show the difference of GFP expression between
15 treated and untreated HeLa cells. According to the quanti-
tative analysis by flow cytometry (FIG. 6), the concentration
of VLP-hpmiRNA required to inhibit 50% of GFP expres-
sion in HeLa cells is 335 nM in 24 hours, and 100 nM in 48
hours (FIG. 7). The results indicate that the eflicienty of
20 VLP-hpmiRNA is high and is both concentration and time
dependent. In control experiments high concentration of
WT-VLP (without pre-miRNA) did not show any inhibition
of target gene expression. We claim that VLP-hpmiRNAs
function as controlled release capsules to release pre-
25 miRNA steadily and continuously over time. This unique
feature could extend the time course of the suppression of
target gene expression compared with conventional RNAi
technology.
c. Coat Protein Recognition Tag
30 RNA that is designed for incorporation within VLPs
contains a sequence that is a recognition tag for the bacte-
riophage or virus coat protein of the VLP. Typically the
recognition tag facilitates efficient packaging of the RNA
35 into the VLP. Recognition tags for viral and bacteriophage
coat proteins are known in the art and include, but are not
limited to the q beta bacteriophage coat protein (See, for
example, Witherell, et al., Biochemistry, 28:71-76 (1989)),
the PP7 coat protein (see Lim and Peabody, Nucleic Acids
40 Res., 30 (19) 4138-4144 (2002)). In one embodiment the
recognition tag is a 54-nucleotide RNA containing two
hairpin structures specific for the enterobacteria bacterio-
phage q beta coat protein. The sequence of the tag (SEQ ID
NO. 1) is 5' rUUCCUCGUGCUUAGUAAC-
45 UAAGGAUGAAAUG CAUGUCUAAGACAGCAUC-
UUCGC 3'
d. Sequence for RNA Purification
If necessary, the RNA is designed to include a sequence
to assist the purification of the RNA. In some embodiments
50 the sequence forms an RNA aptamer. RNA aptamers can
assist in the purification of the RNA through affinity chro-
matography with RNA binding proteins. In one embodiment
a sequence (taken from prior art: Nucleic Acids Research,
55 
2001, VO1.29, No. 2 e4) that assists in the purification of the
RNA is located at the opposite end of the RNA polynucle-
otide to the bacteriophage or viral coat protein recognition
tag. The sequence of the RNA tag (SEQ ID NO. 2) is 5'
CAGCAAGUUCCGCAACCGUA
60 UCAAAACGUAAAUUACUCGGAC3'
2. Viral Coat Protein
VLP-RNAs include bacteriophage or viral coat proteins.
Viral or bacteriophage coat proteins are known in the art and
include the enterobacteria bacteriophage Q beta coat protein
65 and the bacteriophage PP7 coat protein. An exemplary
nucleotide sequence for genes encoding the bacteriophage Q
beta coat protein is
US 9,932,563 B2
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46 atggc aaaattagag
61 actgttactt taggtaacat cgggaaagat ggaaaacaaa ctctggtcct caatccgcgt
121 ggggtaaatc ccactaacgg cgttgcctcg ctttcacaag cgggtgcagt tcctgcgctg
181 gagaagcgtg ttaccgtttc ggtatctcag ccttctcgca atcgtaagaa ctacaaggtc
241 caggttaaga tccagaaccc gaccgcttgc actgcaaacg gttcttgtga cccatccgtt
301 actcgccagg catatgctga cgtgaccttt tcgttcacgc agtatagtac cgatgaggaa
361 cgagcttttg ttcgtacaga gcttgctgct ctgctcgcta gtcctctgct gatcgatgct
421 attgatcagc tgaacccagc gtattga
(from SEQ ID NO. 3). GenBank: M99039.1.
An exemplary amino acid sequence for the bacteriophage
Q beta coat protein gene is
10 20 30 40
MAKLETVTLG NIGKDGKQTL VLNPRGVNPT NGVASLSQAG
50 60 70 80
AVPALEKRVT VSVSQPSRNR KNYKVQVKIQ NPTACTANGS
90 100 110 120
CDPSVTRQAY ADVTFSFTQY STDEERAFVR TELAALLASP
130
LLIDAIDQLN PAY
(SEQ ID NO. 4)
II. Methods for Making and Using VLPs
Containing RNA
Methods for the production of VLPs containing RNA are
provided. Methods for the purification and delivery of the
VLPs containing RNA are also provided.
A. Production of VLPs Containing RNA
Methods for single-step production of VLPs containing
RNA are disclosed. The methods can be used, for example,
for the production and packaging of RNA into VLPs.
Typically, the expression of RNA is greater in the prokary-
otic expression system when the RNA is sequestered and
packaged into VLPs than when RNA is produced alone. The
RNA and VLPs self-assemble with high specificity into
"VLP-RNAs" when the RNA is fused the appropriate tag
(for example, an RNA hairpin sequence). The methods do
not impose any limitation on the structure of the RNA that
is to be packaged within the VLPs. VLP packaged RNAs can
be long or short, single-stranded or double-stranded, and can
be of any sequence.
The purification of VLPs containing RNA produced by
the disclosed methods is trivial, and is simpler than the
purification of unpackaged RNA. VLPs protect the enclosed
RNAs from chemical, photo- and enzymatic degradation.
The RNA in a VLP is stabilized against degradation by
nucleases, hydroxyl radical, UV light, and Mg2'-mediated
inline attack. VLPs eliminate requirements for chemical
modification to stabilize and deliver RNA. The high-stabil-
ity of VLP-RNAs enables storage for long periods of time
and allows for a broad range of application methods, includ-
ing distribution as aerosols, solutions, powders, etc. The
VLP-RNAs are readily taken up by many cell types and
efficiently deliver RNA to biological targets. Furthermore,
production and usage of VLPs containing RNA is water-
based and environmentally sound. RNA within VLP is stable
indefinitely at room temperature. [We are doing a lot of
10
15 experiments to characterize RNA stability under extreme
conditions (Temp, UV, etc) and can add a subsection on this
later]
1. Expression of VLP Genes and RNA
20 For the expression of VLPs and RNA, the host organism
is transformed with plasmids that express genes for the coat
protein of a bacteriophage or virus in addition to one or more
RNA gene(s).
Typically, the genes) encoding RNA and genes encoding
25 bacteriophage or viral coat proteins are cloned into an
expression system for the expression of VLPs containing
RNA in vivo. Suitable expression systems are known in the
art (see, for example, Studier, Protein Expr Purif, 41:
207-234. (2005)). The coat protein is expressed in the
30 pCDF-lb expression vector. The RNA is expressed in either
pET-28b or pUC-19.
In some embodiments, the in vivo expression of RNA
occurs in a prokaryote. Prokaryotes commonly utilized for
the expression of RNA include, but are not limited to
35 bacteria such as Escherichia spp., Bacillus spp. and Ther-
mophilus spp. In one embodiment the host organism for in
vivo production of VLPs containing RNA is Escherichia
coli. Useful Escherichia coli strains for expressing and
producing polypeptides are well known in the art. The
4o BL21(DE3) strain of E. coli is used to express the protein
and RNA.
Expression cassettes that are designed for the expression
of RNA can be easily transferred to a transformation vector
for transfer to the host organism and transformation tech-
45 niques are well known in the art. The one or more genes
encoding RNA and the one or more genes encoding the coat
protein of a bacteriophage or virus can be encoded within the
same expression construct, or may be encoded within two or
more different expression constructs. The genes can be
50 under the control of the same or different promoter elements.
In some embodiments the expression of the VLPs containing
RNA is under the control of an inducible promoter. An
exemplary inducible promoter is the Isopropyl-p-D-thioga-
lactopyranoside (IPTG) inducible promoter.
55 2. Assembly of VLPs Containing RNA
The disclosed methods provide one or more RNA genes
and viral or bacteriophage coat proteins that spontaneously
assemble in vivo into intact "VLP-RNAs". The RNA and
VLPs self-assemble with high specificity into VLP-RNAs
60 when the RNA is fused to the appropriate tag (for example,
an RNA hairpin sequence). In one embodiment, VLPs
containing RNA are expressed in high yield in Escherichia
coli cells.
In one embodiment the RNA packaged within the VLP is
65 at least 80% pure. In other embodiments the RNA is at least
85% pure, at least 90% pure or at least 95% pure. Typically
one VLP vessel contains at least one RNA molecule. In one
US 9,932,563 B2
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embodiment the RNA is packaged within the VLPs at an
RNA/VLP molar ratio of about 3.6, such that each VLP
packs approximately three RNA molecules.
3. Purification of VLPs Containing RNA.
Because of their distinctive size, properties and high
stability, VLPs can be easily purified from Escherichia coli
cellular lysates. The purification of VLPs containing RNA
(VLP-RNAs) produced by the disclosed methods is straight-
forward, and is simpler than the purification with fast protein
liquid chromatography (FPLC), filtration, sedimentation,
sucrose-gradient separation, aflinity tag chromatography and
flow-field fractionation multi-angle light scattering (FFF-
MALS). In some embodiments purification of the VLPs
containing RNA includes pelleting of the host organism
cells. The pelleted cells or isolated VLPs can be frozen or
dried for storage or distribution purposes.
4. Delivery of Purified VLPs Containing RNA
VLPs protect the enclosed RNAs from chemical, photo-
and enzymatic degradation. The RNA in a VLP is stabilized
against degradation by nucleases, hydroxyl radical, UV
light, and Mg2'-mediated inline attack. VLPs eliminate
requirements for chemical modification to stabilize and
deliver RNA. The high-stability of VLP-RNAs enables
storage for long periods of time and allows for a broad range
of application methods, including distribution as aerosols,
solutions, powders, etc. The VLPs are readily taken up by
many cell types and efficiently deliver RNA to biological
targets.
In one embodiment purified VLPs containing RNA are
introduced into a complex eukaryotic organism by ingestion
of doped food. When the VLPs are taken up by target cells,
the RNA is released and the biological activity of the
enclosed RNA is manifest. VLPs containing RNA can be
delivered as crude cell extracts. In other embodiments they
can be left within the pelleted Escherichia coli and delivered
as intact Escherichia coli cells.
B. Applications of VLPs Containing RNAs
1. Therapeutics
In some embodiments VLPs containing RNA are used for
the delivery of RNA for applications in therapeutics. In
certain embodiments, the targeting of gene expression by the
RNA is an effective therapeutic strategy against infectious
disease, cancer, inflammatory disease, etc. In one embodi-
ment, VLPs containing RNAs are used to deliver a RNA-
based functional cure for hepatitis B, which infects over 300
million people world-wide.
2. Agriculture.
In some embodiments VLPs containing RNA are used for
the protection of plants from weeds and insects and for
increasing crop yields. In certain embodiments, the targeting
of gene expression by the RNA enables the production of
allergy-free peanuts and decaffeinated coffee beans. In one
embodiment, VLPs are used to deliver RNA to kill mites that
parasitize honeybees.
3. Biofuels
In some embodiments VLPs containing RNAs are used
for the delivery of RNA designed to substantially improve
solar-driven hydrogen production by microalgae.
4. Research Tools
In some embodiments VLPs containing RNAs are used
for research tools. In one embodiment the RNAs are used for
the study of loss of function due to silencing of target genes
by RNA, for example to assist in elucidating gene function.
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EXAMPLES
Example I
5 Construction of a VLP Containing RNA
Materials and Methods
RNA Design and Expression
Using Known methods, one or more genes are built by
10 
recursive PCR or are cloned from a cDNA or genomic
library. The genes, along with promoters and terminators,
are DNA sequences designed to express the desired RNAs.
The genes can be of any desired sequence and can encode
15 either double-stranded or single-stranded RNAs. RNAs of
essentially any length and sequence can be produced in high
yield in Escherichia coli. The RNA gene(s) are cloned into
an inducible expression system.
Assembly and Purification of VLPs Containing RNA.
20 The RNA is designed to contain a recognition tag that
confers high amity for a bacteriophage or virus coat protein
along with a known aptamer for RNA purification, if nec-
essary. The recognition tag facilitates efficient packaging of
the RNA into the VLP.
25 In this process, Escherichia coli are transformed with
plasmids that express the RNA gene(s) in addition to genes
for the coat protein of a bacteriophage or virus. The
expressed coat protein spontaneously assembles in vivo into
intact VLPs that contain RNAs (VLP-RNAs). Because of
30 their distinctive size, properties and high stability, VLPs can
be easily purified from Escherichia coli cellular lysates.
Delivery.
Purified VLP-RNAs can be introduced into a complex
35 eukaryotic organism by ingestion of doped food. When the
VLP-RNAs are taken up by target cells, the RNA is released
and the biological activity of the RNA is manifest. VLP-
RNAs can be delivered as crude cell extracts. In addition
they can be left within the pelleted Escherichia coli and
40 delivered as intact Escherichia coli cells.
Results
A simple, robust, general and adaptable in vivo system in
Escherichia coli that produces and packages RNA into VLPs
was built. An integrated process for (i) Simultaneous over-
45 production of RNA and a bacteriophage coat protein, (ii) in
vivo self-assembly of VLP-RNAs, was designed, con-
structed and successfully tested.
RNA was packaged into a VLP by co-expression of the
capsid protein and the RNA in vivo. The RNA, which was
50 obtained by disruption of purified VLPs, contains a capsid
binding tag along with a secondary amity tag at a terminus
for optional purification. The RNA, including the duo tags,
is 751 nucleotides in length, corresponding to the brightest
55 
band in the lane on the LH side. Integration of the band
intensities on the gel suggests that the RNA is 80% pure.
Comparison of quantity of VLP capsid protein with encap-
sulated RNA indicates an RNA/VLP molar ratio of 3.6. This
ratio suggests that, on average, one VLP packs about three
60 RNA molecules (see FIG. 1).
These data demonstrate that VLP-RNAs assemble and are
efficiently packaged with the tagged-RNA when both coat
protein and RNA are over produced in Escherichia coli.
VLP-RNAs, the protein and RNA components of VLP-
65 RNAs were purified and characterized (see FIG. 1). The
sequence of the RNA used in this example (SEQ ID NO. 5)
is 5'
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5' rGUCCGAGUAAUUUACGUUUUGAUACGGUUGCGGAACUUGCGGGGUG
CCUAUUGAAGCAUGAGCCGGCGACUCAGCCGUAAGGCUGGACCCGAAACC
GGGCGAGCUAGCCCUGGCCAGCCGUAAGGCGAACCGGUGGGGGAUGCAAA
CCCCUCGGAUGAGCUGGGGCUAGGAGUGAAAAGCUAACCGAGCCCGGAGA
UAGCUGGUUCUGCCGUAAGGCAGCGUUGCCGUAAGGCAAGUGCGAAUGCC
GGCAUGAGUAACGAGCGGGAGAACCCUCGCCAAGGAACUCUGCAAGCCGU
AAGGCCUCUGGCGACUGUUUACCAAAAACACAGCGCCGUAAGGCGCGAGC
CGUAAGGCUAACGACCGGAGCGCUGUCUCGGCGAGGGACCCGGUGAAAUU
GAACUGGCCGUGAAGAUGCGGCCUACCCGUGGCAGGACGAAAAGACCCCG
UGGAGCUUUACUGCCGUAAGGCAGUUUGACUGGGGCGGUCGGCCGUAAGG
CUAAAAGUUACCCCGGGGAUAACAGGCUGAUCGCCGUAAGGCGGUUUGGC
ACCUCGAUGUCGGCUCGUCGCGCCGUAAGGCUUGGGCUGUUCGCCCAUUA
AAGCGGCACGCGAGCUGGGUUCAGAACGUCGUGAGACAGUUCGGUCUCUA
UCCGCCACGGGCUUCCUCGUGCUUAGUAACUAAGGAUGAAAUGCAUGUCU
AAGACAGCAUCUUCGC 3'
Example 2
VLPs Containing RNA Selectively Target and Kill
Target Insects
Materials and Methods
Strategy
Delivery of RNA to a biological target using VLPs
containing RNA (VLP-RNAs) and efficacy of the VLP-
RNAs was demonstrated with the eastern subterranean ter-
mite Reticulitermes flavipes workers, an insect that causes
economically significant damage to buildings and crops
system in which RNA interference feeding approaches were
previously shown to silence genes.
Delivery and Assay for Eflicacy of VLPs Containing RNA
An active VLP-RNA was designed to selectively target
the cellulose gene, a critical digestive gene of Reticulitermes
flavipes (VLP-RNA-cellulase). A solution containing 600 µg
of VLP-RNA-cellulase was added each day to filter paper
and the survival of Reticulitermes flavipes workers consum-
ing the VLP-RNA-cellulase doped paper was monitored
throughout 14 days. A control group of termites consumed
filter paper treated with buffer alone.
Results
RNA is protected by VLPs in unfavorable environments.
Denaturing polyacrylamide gel analysis of naked RNA and
VLP-packaged RNA for different time intervals shown on
left column (FIGS. 2A, 2C, and 2E). Major RNA band level
expressed as a percentage of the initial value was plotted
versus time with different treatment shown on right column
(FIGS. 213, 2D, and 2F). Naked RNA and VLP-packaged
RNA are treated. Hydroxyl radical cleavage: samples were
treated with free hydroxyl radicals that were created from
the Fenton reaction (FIGS. 2A-213). Metal ion-based cleav-
age: samples were treated with 150 mM Mg2l ions at 37° C.
(FIGS. 2C-2D). Spontaneous degradation: samples were
treated without Mg2l ions at 37° C. (FIGS. 2E-2F).
FIG. 3 is a scatter dot plot to illustrate the survival of the
Eastern subterranean termite Reticulitermes flavipes (as a
fraction of the starting quantity), over time (in days), for
14
termites consuming filter paper containing 600 µg VLP-
sRNA (■) or a control containing buffer (0), respectively.
FIG. 4 shows the uptake of dual-color virus like particles
(VLPs) by HeLa cells: The Q(3-VLPs encapsulate the green
5 fluorescent protein (GFP) in vitro, where the particle surface
is chemically conjugated with the fluorescent dye, Dylight
633. The HeLa cells were incubated with 125 nM of
[Q(3-VLP-GFP-Dylight633] at 37° C. for 0, 1, and 2 days. If
10 
Q(3-VLP encapsidates green fluorescent proteins and forms
a complex, the co-localization will possess unique emission.
Therefore, GFP-loaded Q(3-VLPs were tracked using con-
focal laser scanning microscopy.
The in vivo VLP-packaged pre-miRNA knocks down the
15 GFP gene expression in HeLa cells. The pre-miRNA
designed to knock down the GFP gene expression is packed
by the production of VLP simultaneously in vivo. Prior to
the incubation of the in vivo VLP-packaged pre-miRNA
with HeLa cells, the GFP gene was first chemically trans-
20 fected into HeLa cells. The GFP gene expression level was
then observed by using fluorescence microscopic tech-
niques. The HeLa cells are treated with (FIG. 5A) as control,
no GFP gene transfection, (FIG. 513) the GFP gene trans-
fection, (FIG. 5C) the in vivo VLP-packaged miRNA after
25 the GFP gene transfection, and (FIG. 5D) the wild type VLP
contains no designed pre-miRNA after the GFP gene trans-
fection. The images were taken for each condition setup
after 24 hours. The VLP concentration is 1 uM. In the
images, white spots show the GFP gene expressions.
30 FIG. 6 shows the gene expression level of GFP in HeLa
cells with the treatments of in vivo VLP-packaged pre-
miRNA (VLP-pre-miRNA) in a concentration fashion for 24
(grey bar) and 48 (black bar) hours. The GFP gene expres-
sion levels, reported here as percentage, were analyzed by
35 the BD LSR II Flow Cytometer. The wild type VLP (WT-
VLP), which contains no designed pre-miRNA to knock
down the GFP gene expression, is used to test the cell
toxicity. The standard deviations (black vertical line) for
each condition are shown on each bar.
40 FIG. 7 is a GFP suppression curve with VLP-packaged-
pre-miRNA at 8 different concentrations up to 48 hours:
Shown are one-phase decay curve models fitted to the GFP
gene expression data in HeLa cells with the treatments of in
vivo VLP-packaged pre-miRNA (VLP-pre-miRNA) in a
45 concentration fashion for 24 (dot line) and 48 (inverted
triangle line) hours. The concentrations for VLP-pre-
miRNA to inhibit 50% of the GFP expression (IC50) in
HeLa cells are 335 nM in 24 hours, and 100 nM in 48 hours.
VLP-RNA-cellulase acted by down-regulating expression of
50 the critical cellulase digestive gene, and depriving the insect
of nutrients causing starvation and complete mortality in the
experimental group by day 13. Control termites consuming
filter paper treated with buffer alone survived indefinitely
(FIG. 3).
55 VLPs function as controlled release capsules to release
pre-miRNA steadily and continuously over time. This
unique feature could extend the time course of the suppres-
sion of target gene expression compared with conventional
RNAi technology.
60
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<210> SEQ ID NO 1
<211> LENGTH: 54
<212> TYPE: RNA
<213> ORGANISM: Bacteriophage Q beta
<400> SEQUENCE: 1
uuccucgugc uuaguaacua aggaugaaau gcaugucuaa gacagcaucu ucgc 54
<210> SEQ ID NO 2
<211> LENGTH: 42
<212> TYPE: RNA
<213> ORGANISM: Bacteriophage Q beta
<400> SEQUENCE: 2
cagcaaguuc cgcaaccgua ucaaaacgua aauuacucgg ac 42
<210> SEQ ID NO 3
<211> LENGTH: 402
<212> TYPE: DNA
<213> ORGANISM: Bacteriophage Q beta
<400> SEQUENCE: 3
atggcaaaat tagagactgt tactttaggt aacatcggga aagatggaaa acaaactctg 60
gtcctcaatc cgcgtggggt aaatcccact aacggcgttg cctcgctttc acaagcgggt 120
gcagttcctg cgctggagaa gcgtgttacc gtttcggtat ctcagccttc tcgcaatcgt 180
aagaactaca aggtccaggt taagatccag aacccgaccg cttgcactgc aaacggttct 240
tgtgacccat ccgttactcg ccaggcatat gctgacgtga ccttttcgtt cacgcagtat 300
agtaccgatg aggaacgagc ttttgttcgt acagagcttg ctgctctgct cgctagtcct 360
ctgctgatcg atgctattga tcagctgaac ccagcgtatt ga 402
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<210> SEQ ID NO 4
<211> LENGTH: 133
<212> TYPE: PRT
<213> ORGANISM: Bacteriophage Q beta
<400> SEQUENCE: 4
Met Ala Lys Leu Glu Thr Val Thr Leu Gly Asn Ile Gly Lys Asp Gly
1 5 10 15
Lys Gin Thr Leu Val Leu Asn Pro Arg Gly Val Asn Pro Thr Asn Gly
20 25 30
Val Ala Ser Leu Ser Gin Ala Gly Ala Val Pro Ala Leu Glu Lys Arg
35 40 45
Val Thr Val Ser Val Ser Gin Pro Ser Arg Asn Arg Lys Asn Tyr Lys
50 55 60
Val Gin Val Lys Ile Gin Asn Pro Thr Ala Cys Thr Ala Asn Gly Ser
65 70 75 80
Cys Asp Pro Ser Val Thr Arg Gin Ala Tyr Ala Asp Val Thr Phe Ser
85 90 95
Phe Thr Gin Tyr Ser Thr Asp Glu Glu Arg Ala Phe Val Arg Thr Glu
100 105 110
Leu Ala Ala Leu Leu Ala Ser Pro Leu Leu Ile Asp Ala Ile Asp Gin
115 120 125
Leu Asn Pro Ala Tyr
130
<210> SEQ ID NO 5
<211> LENGTH: 712
<212> TYPE: RNA
<213> ORGANISM: Bacteriophage Q beta
<400> SEQUENCE: 5
guccgaguaa uuuacguuuu gauacgguug cggaacuugc ggggugccua uugaagcaug 60
agccggcgac ucagccguaa ggcuggaccc gaaaccgggc gagcuagccc uggccagccg 120
uaaggcgaac cgguggggga ugcaaacccc ucggaugagc uggggcuagg agugaaaagc 180
uaaccgagcc cggagauagc ugguucugcc guaaggcagc guugccguaa ggcaagugcg 240
aaugccggca ugaguaacga gcgggagaac ccucgccaag gaacucugca agccguaagg 300
ccucuggcga cuguuuacca aaaacacagc gccguaaggc gcgagccgua aggcuaacga 360
ccggagcgcu gucucggcga gggacccggu gaaauugaac uggccgugaa gaugcggccu 420
acccguggca ggacgaaaag accccgugga gcuuuacugc cguaaggcag uuugacuggg 480
gcggucggcc guaaggcuaa aaguuacccc ggggauaaca ggcugaucgc cguaaggcgg 540
uuuggcaccu cgaugucggc ucgucgcgcc guaaggcuug ggcuguucgc ccauuaaagc 600
ggcacgcgag cuggguucag aacgucguga gacaguucgg ucucuauccg ccacgggcuu 660
ccucgugcuu aguaacuaag gaugaaaugc augucuaaga cagcaucuuc gc 712
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We claim: 2. The VLP containing RNA of claim 1 wherein the RNA
1. A virus like particle (VLP) containing ribonucleic acid 60 is processed in vivo into short interfering RNAs (siRNAs).
(RNA) comprising 3. The VLP containing RNA of claim 1 wherein the
a) a virus like particle formed from coat proteins of a bacteriophage coat protein is the bacteriophage q beta coatbacteriophage; and
b) RNA comprising a capsid binding tag, wherein the protein.
capsid binding tag comprises SEQ ID NO:I;and 65 4. The VLP containing RNA of claim 1 wherein the VLP
wherein the coat proteins of the bacteriophage self-as- stabilizes the RNA against chemical, photochemical and
semble to encapsidate three of the RNAs per VLP. enzymatic degradation processes.
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5. The VLP containing RNA of claim 1 wherein the RNA
comprises one or more selected from the group consisting of
thermal-stable tetraloops, G-quartets, and triple strands.
6. The VLP containing RNA of claim 1 wherein the RNA
is at least 180 nucleotides in length. 5
7. The VLP containing RNA of claim 1 wherein the RNA
is inhibitory RNA specific for cellulase of a cellulose
dependent insect.
8. The VLP containing RNA of claim 7 wherein the
cellulose dependent insect is the eastern termite Reticuli- io
termes flavipes.
9. The VLP containing RNA of claim 1 wherein the RNA
is inhibitory RNA specific tumor-specific transcription fac-
tors.
10. The VLP containing RNA of claim 1 wherein the RNA 15
is inhibitory RNA specific for regulators of cellular prolif-
eration.
11. The VLP containing RNA of claim 1 wherein the
target mRNA encodes proteins of infectious pathogens.
12. The VLP containing RNA of claim 1 wherein the RNA 20
further contains a sequence tag for purification of the RNA.
13. The VLP containing RNA of claim 1, wherein the
VLP is spontaneously taken up by human, insect, plant and
other cells.
